Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Short Interest Down 43.7% in July

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) was the recipient of a large decrease in short interest in the month of July. As of July 15th, there was short interest totaling 80,592 shares, a decrease of 43.7% from the June 30th total of 143,052 shares. Approximately 6.8% of the shares of the company are sold short. Based on an average trading volume of 183,392 shares, the days-to-cover ratio is currently 0.4 days.

Regentis Biomaterials Stock Down 3.3%

Shares of NYSEAMERICAN:RGNT traded down $0.06 during trading on Friday, reaching $1.74. 128,369 shares of the stock were exchanged, compared to its average volume of 122,867. Regentis Biomaterials has a 12 month low of $1.23 and a 12 month high of $15.50. The company’s 50-day moving average is $2.94.

Institutional Trading of Regentis Biomaterials

A hedge fund recently bought a new stake in Regentis Biomaterials stock. AIGH Capital Management LLC acquired a new stake in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned approximately 5.79% of Regentis Biomaterials at the end of the most recent reporting period.

About Regentis Biomaterials

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.